IconOVir Bio

IconOVir Bio is a preclinical-stage biotechnology company founded in 2018 with the mission to cure cancer and restore life to every patient everywhere. The company's proprietary oncolytic virus platform, developed by scientific founder Clodagh O’Shea, Ph.D., of the Salk Institute, aims to address key limitations of first- and second-generation oncolytic viruses. The $77.00M Series A investment received on 05 January 2021 reflects the confidence of investors such as GV, Polaris Partners, Wellington Partners, Bellco Capital, Logos Capital, Nextech Invest, Two River, and Vida Ventures. With its focus on biotechnology and its headquarters in the United States, IconOVir Bio is pushing the envelope in revolutionary cancer treatment.